Beam Therapeutics Reports Pipeline Updates and First Quarter

Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives ... | May 10, 2023

Related Keywords

North Carolina , United States , Cambridge , Cambridgeshire , United Kingdom , American , Los Angeles , John Evans , Dan Budwick , Gopi Shanker , Chelcie Lister , Program Updates , Beam Therapeutics Inc , Hematology Program Updates , Nasdaq , Research Development Rd Expenses , American Society Of Gene , Strategic Communications , Exchange Commission , Immunology Oncology Program Updates , Executing Three Strategic Pillars , Genetic Diseases , Long Term Pipeline Growth , Sustained Impact , Sites Activated , Additional Patients Enrolled , Sickle Cell , Year Industry Veteran , Chief Scientific , Cash Equivalents , Marketable Securities , First Quarter , Engineered Stem Cell Antibody Paired Evasion , American Society , Cell Therapy , Potential Treatment , Friday Poster , Mediated Adenine Base , Friday May , Gene Targeting , Gene Correction , Private Securities Litigation Reform Act , Annual Report , Consolidated Balance Sheet Data , Consolidated Statement , Months Ended March , Beam Therapeutics Inc Stock Exchange , News , Information , Press Release , Ocused , N , Executing , Three , Strategic , Pillars , End , Enetic , Diseases , Potential , Or , Pipeline , Growth , Sustained , Impact , Patient , Ives Beam Us07373v1052 ,